Integrative clinical genomics of metastatic cancer

Nature

Volumn 548, Issue 7667, 2017, Pages 297-303

  Robinson, Dan R ^a,b   Wu, Yi Mi ^a,b   Lonigro, Robert J ^a   Vats, Pankaj ^a   Cobain, Erin ^b   Everett, Jessica ^b   Cao, Xuhong ^a   Rabban, Erica ^a   Kumar Sinha, Chandan ^a,b   Raymond, Victoria ^b   Schuetze, Scott ^b   Alva, Ajjai ^b   Siddiqui, Javed ^a,b   Chugh, Rashmi ^b   Worden, Francis ^b   Zalupski, Mark M ^b   Innis, Jeffrey ^b   Mody, Rajen J ^b   Tomlins, Scott A ^a,b   Lucas, David ^b   Baker, Laurence H ^b   Ramnath, Nithya ^b   Schott, Ann F ^b   Hayes, Daniel F ^b   Vijai, Joseph ^c   Offit, Kenneth ^c   Stoffel, Elena M ^b   Roberts, J Scott ^d   Smith, David C ^b   Kunju, Lakshmi P ^a,b   Talpaz, Moshe ^d   Cieślik, Marcin ^a,b   Chinnaiyan, Arul M ^a,b,d,e   more..

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CDKN2A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P53; PTEN PROTEIN, HUMAN; RB1 PROTEIN, HUMAN; RETINOBLASTOMA BINDING PROTEIN; TP53 PROTEIN, HUMAN; TRANSCRIPTOME; UBIQUITIN PROTEIN LIGASE;

ADULT; DNA REPAIR; FEMALE; GENETICS; GENOMICS; GERMLINE MUTATION; HUMAN; IMMUNOLOGY; MALE; MEDICAL GENETICS; METASTASIS; PATHOLOGY; TUMOR MICROENVIRONMENT; WHOLE EXOME SEQUENCING;

ADULT; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DNA REPAIR; FEMALE; GENETICS, MEDICAL; GENOMICS; GERM-LINE MUTATION; HUMANS; MALE; NEOPLASM METASTASIS; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA BINDING PROTEINS; TRANSCRIPTOME; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; WHOLE EXOME SEQUENCING;

EID: 85027893400     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23306     Document Type: Article

References (45)

1. Mehlen, P. & Puisieux, A. Metastasis: a question of life or death. Nat. Rev. Cancer 6, 449-458 (2006).
2. Steeg, P. S. Targeting metastasis. Nat. Rev. Cancer 16, 201-218 (2016).
3. Friedman, A. A., Letai, A., Fisher, D. E. & Flaherty, K. T. Precision medicine for cancer with next-generation functional diagnostics. Nat. Rev. Cancer 15, 747-756 (2015).
4. Mauer, C. B., Pirzadeh-Miller, S. M., Robinson, L. D. & Euhus, D. M. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet. Med. 16, 407-412 (2014).
5. Shen, T., Pajaro-Van de Stadt, S. H., Yeat, N. C. & Lin, J. C. Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. Front. Genet. 6, 215 (2015).
6. Jones, S. et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci. Transl. Med. 7, 283ra53 (2015).
7. Roychowdhury, S. et al. Personalized oncology through integrative highthroughput sequencing: a pilot study. Sci. Transl. Med. 3, 111ra121 (2011).
8. Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D. & Craig, D. W. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat. Rev. Genet. 17, 257-271 (2016).
9. Turajlic, S. & Swanton, C. Metastasis as an evolutionary process. Science 352, 169-175 (2016).
10. Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215-1228 (2015).
11. The Cancer Genome Atlas Research Network, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113-1120 (2013).
12. Gagan, J. & Van Allen, E. M. Next-generation sequencing to guide cancer therapy. Genome Med. 7, 80 (2015).
13. Mardis, E. R. The translation of cancer genomics: time for a revolution in clinical cancer care. Genome Med. 6, 22 (2014).
14. Parsons, D. W. et al. Diagnostic yield of clinical tumor and germline wholeexome sequencing for children with solid tumors. J. Am. Med. Assoc. Oncol. 2, 616-624 (2016).
15. Mody, R. J. et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. J. Am. Med. Assoc. 314, 913-925 (2015).
16. Wagle, N. et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2, 82-93 (2012).
17. Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443-453 (2016).
18. Palanisamy, N. et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16, 793-798 (2010).
19. Robinson, D. R. et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat. Med. 17, 1646-1651 (2011).
20. Stransky, N., Cerami, E., Schalm, S., Kim, J. L. & Lengauer, C. The landscape of kinase fusions in cancer. Nat. Commun. 5, 4846 (2014).
21. Agaram, N. P., Zhang, L., Sung, Y. S., Singer, S. & Antonescu, C. R. Extraskeletal myxoid chondrosarcoma with non-EWSR1-NR4A3 variant fusions correlate with rhabdoid phenotype and high-grade morphology. Hum. Pathol. 45, 1084-1091 (2014).
22. Weinreb, I. et al. Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosom. Cancer 53, 845-856 (2014).
23. Amir, A. D. et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol. 31, 545-552 (2013).
24. Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580-585 (2013).
25. Liberzon, A. et al. The Molecular Signatures Database hallmark gene set collection. Cell Syst. 1, 417-425 (2015).
26. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739-1740 (2011).
27. Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).
28. Vaske, C. J. et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237-i245 (2010).
29. López-Novoa, J. M. & Nieto, M. A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 1, 303-314 (2009).
30. Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).
31. Attig, S. et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res. 69, 8412-8419 (2009).
32. Nakano, O. et al. Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61, 5132-5136 (2001).
33. Ruffini, E. et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann. Thorac. Surg. 87, 365-371 (2009).
34. Boon, T., Coulie, P. G., Van den Eynde, B. J. & van der Bruggen, P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175-208 (2006).
35. Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453-457 (2015).
36. Sica, A., Schioppa, T., Mantovani, A. & Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717-727 (2006).
37. Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847-856 (2015).
38. van Houdt, I. S. et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int. J. Cancer 123, 609-615 (2008).
39. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
40. Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
41. Ulloa-Montoya, F. et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 31, 2388-2395 (2013).
42. Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697-1708 (2015).
43. Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 8, 193-204 (2008).
44. Cieślik, M. et al. The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res. 25, 1372-1381 (2015).
45. Leiserson, M. D. et al. MAGI: visualization and collaborative annotation of genomic aberrations. Nat. Methods 12, 483-484 (2015).